Daniel Scanlon Email & Phone Number

Verdacom was formed by a team of seasoned industry veterans with hands-on clinical trials experience. These individuals bring specific core talents as well as the drive, passion, and an unequaled insight on “best practice” methods to streamline and perfect the complex process of collecting, tracking, reporting and managing enrollment and inventory data.Verdacom’ s principles are key players in the development and growth of the clinical trials information technology industry. We have pioneered new, more efficient methods of data capture and management. We were at the forefront of evolving inventory management and randomization services including to just-in-time management practices. We are technological innovators with years of experience developing new applications to facilitate data visualization from ever changing technologies. And, we have saved major companies hundreds of millions of dollars.At Verdacom, we believe choosing the right team is one of the keys to success. When you choose Verdacom you will have chosen experienced people with a true passion for their work.You will have chosen a knowledgeable and dedicated people that will embrace your project, provide guidance if asked and prove themselves a valuable part of your team.

Founded and grew an organization based on technology, service, sound business practice and excellent staff. ICTI quickly became the vendor of choice for many of the top 10 pharmas and major biotechs.ICTI became part of the Galen organization and now lives on as Almac.

Developed and maintained internal and external clinical data management systemsHad various responsibilities including infrastructure maintenance, user support, support of internal systems such as financial, project management, business development and clinical data entry, protocol and investigator databases.Most importantly was involved in the first large scale IVRS implementation for inventory management and randomization services for a major clinical trial. Further refined and promoted the commercialization of IVRS as a valuable tool to reduce cost and speed startup of clinical trials.